New drug called Aimovig (erenumab-aooe) targets a specific receptor in the brain to reduce the frequency of migraine in adults
Migraine is characterized by headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. An estimated of one-third of affected individuals can predict the onset of a migraine due to it is preceded by an aura – transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision.
After successful and safe clinical trials, the U.S. Food and Drug Administration (FDA) approved Aimovig for the preventive treatment of migraine in adults. It is the first novel class of drugs designed to block the activity of a specific peptide, which is known to activate migraines. The drug is named as erenumab and it is marketed under the name Aimovig. It functions by blocking calcitonin gene-related peptide receptors (CGRP-R) in the brain, which are known as critical migraine activators. As a part of clinical trials, it was reported that individuals suffering from chronic migraines experienced significant reduction in the frequency of migraine attacks.
“Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine,” said Paul Hudson, CEO Novartis Pharmaceuticals. “We look forward to working closely with Amgen in the U.S. to bring this treatment to physicians and their patients, who could now gain days of their lives back each month.” Aimovig is recommended to be taken once a month, as a self-administered injection. It comes is avaible in two different dosage tiers and does not require any sort of loading dose. However, the drug is expensive and it is priced at US$ 575 in the U.S. for single monthly dose. Aimovig is just one of four different treatments currently in development that target CGRP receptors.